ArticleFrontiers in pharmacology2022

Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China.

Shanshan Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.